INFORMED CONSENT FOR MEDICATION
Dosage and/or Side Effect information last revised on 08/20/2020

Completion of this form is voluntary. If not completed, the medication cannot be administered without a court order unless in an emergency. This consent is maintained in the client’s record and is accessible to authorized users.

<table>
<thead>
<tr>
<th>MEDICATION CATEGORY</th>
<th>MEDICATION</th>
<th>RECOMMENDED DAILY TOTAL DOSAGE RANGE</th>
<th>ANTICIPATED DOSAGE RANGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antipsychotic Agent</td>
<td>Navane (thiothixene)</td>
<td>Oral: 6 mg - 60mg</td>
<td></td>
</tr>
</tbody>
</table>

The anticipated dosage range is to be individualized, may be above or below the recommended range but no medication will be administered without your informed and written consent. Recommended daily total dosage range of manufacturer, as stated in Physician’s Desk Reference (PDR) or another standard reference. This medication will be administered

- [ ] Orally
- [ ] Injection
- [ ] Other – Specify:

1. **Reason for Use of Psychotropic Medication and Benefits Expected (note if this is ‘Off-Label’ Use)**
   Include DSM-5 diagnosis or the diagnostic “working hypothesis.”

2. **Alternative mode(s) of treatment other than OR in addition to medications include**
   Note: Some of these would be applicable only in an inpatient environment.

   - [ ] Environment and/or staff changes
   - [ ] Positive redirection and staff interaction
   - [ ] Individual and/or group therapy
   - [ ] Rehabilitation treatments/therapy (OT, PT, AT)
   - [ ] Treatment programs and approaches (habilitation)
   - [ ] Use of behavior intervention techniques
   - [ ] Other Alternatives:

3. **Probable consequences of NOT receiving the proposed medication are**

   **Impairment of**
   - [ ] Work Activities
   - [ ] Family Relationships
   - [ ] Social Functioning

   **Possible increase in symptoms leading to potential**

   - [ ] Use of seclusion or restraint
   - [ ] Limits on recreation and leisure activities
   - [ ] Limits on access to possessions
   - [ ] Intervention of law enforcement authorities
   - [ ] Limits on personal freedoms
   - [ ] Risk of harm to self or others
   - [ ] Limit participation in treatment and activities

   **Other Consequences:**

---

Note: These consequences may vary depending upon whether or not the individual is in an inpatient setting. It is also possible that in unusual situations, little or no adverse consequences may occur if the medications are not administered.
Most Common Side Effects: constipation; changes in sweating; dizziness, lightheadedness, or fainting; drowsiness (mild); dry mouth; increased appetite; increased weight; increased sensitivity of skin to sunlight (skin rash, itching, redness or other discoloration of skin, or severe sunburn); stuffy nose.

Less Common Side Effects: changes in menstrual period; decreased sexual ability; swelling of breasts (in males and females); unusual secretion of milk; blurred vision or other eye problems; difficult urination; difficulty talking or swallowing; inability to move eyes; lip smacking or puckering; loss of balance control; mask-like face; muscle spasms, especially of the neck and back; puffing of cheeks; rapid or worm-like movements of tongue; restlessness or need to keep moving (severe); shuffling walk; stiffness of arms and legs; trembling and shaking of fingers and hands; twisting movements of body; uncontrolled chewing movements; uncontrolled movements of the arms and legs.

Rare Side Effects: Although rare, check with your doctor as soon as possible if any of the following occur: hot, dry skin or lack of sweating; increased blinking or spasms of eyelid; muscle weakness; sore throat and fever; unusual bleeding or bruising; unusual facial expressions or body positions; yellow eyes or skin; seizure; unusual tiredness; unusually pale skin; difficulty breathing; unusually high or low blood pressure.

Stop taking this medicine and get emergency help immediately if any of the following symptoms of Neuroleptic Malignant Syndrome (NMS) occur: fast heartbeat; high fever; severe muscle stiffness; confusion or changes in thinking; severe headache; severe dizziness.

Caution

- Increased sensitivity of the skin to the sun
  This medication may cause your skin to be more sensitive to sunlight than it is normally. Exposure to sunlight, even for brief periods of time, may cause a skin rash, itching, redness or other discoloration of the skin, or a severe sunburn.

- Driving and operating heavy machinery
  This medication may cause you to become dizzy or drowsy, which can be dangerous if planning to drive, operate heavy machinery, or perform any other task that could be hazardous if not fully alert. Wait until you know how this medication affects you before participating in these activities.

- Extrapyramidal symptoms (EPS)
  Patients have reported muscle spasms of the neck and back; shuffling walk; tic-like (jerky) movements of the head, face and neck; trembling and shaking of the hands and fingers; inability to move eyes; mask-like face; loss of balance control; blurred vision; difficulty speaking or swallowing. Additionally, though not common, Tardive Dyskinesia has been reported. Tardive Dyskinesia presents with lip smacking or puckering, puffing of cheeks, rapid or fine worm-like movement of tongue, uncontrolled chewing movement, or uncontrolled movements of arms and legs may occur and may not go away after stopping use of the medication.

- Fall risk
  This medication may increase the risk of experiencing a fall due to dizziness or drowsiness.

- Orthostatic hypotension
  Orthostatic hypotension is lightheadedness or dizziness when standing up from a sitting or lying position. This could lead to fainting and injury. Take caution by standing slowly from a seated or lying position.

- Anticholinergic effects
  May cause anticholinergic effects (constipation, dry mouth, blurred vision, urinary retention).

- Neuroleptic Malignant Syndrome (NMS)
  Use may be associated with NMS. Monitor for changes in thinking, fever, muscle stiffness, and/ autonomic instability (unable to exercise, abnormal sweating, loss of appetite, loss of bladder control, difficulty with ejaculation, blurry vision). Call your doctor as soon as possible if you believe you may have NMS.

- Seizure
  This medication, in rare cases, may increase the chance of experiencing a seizure, especially if an individual has a history of seizures.

- Withdrawal
  Do not abruptly stop taking this medication as it may cause you to experience withdrawal symptoms. Speak with your doctor before stopping this medication.

- QT prolongation
  This medication has the potential to lengthen/ prolong the QT interval. This medication should be avoided, if possible, in those who have Congenital Long QT Syndrome (CLQTS) or those who have multiple risk factors for a prolonged QT interval.
**Warning:** [Black Box Warning]: Increased Mortality in Elderly Patients with Dementia Related Psychosis:

Elderly patients with dementia related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. Analyses of 17 placebo controlled trials (modal duration of 10 weeks, largely in patients taking atypical antipsychotic drugs, revealed a risk of death in the drug treated patients of between 1.6 to 1.7 times that seen in placebo treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug treated patients was about 4.5% compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear.

This drug is not approved for the treatment of patients with dementia-related psychosis.

---

**By my signature below, I GIVE consent for the named medication on Page 1 and anticipated dosage range. My signature also indicates that I understand the following:**

1. I can refuse to give consent or can withdraw my consent at any time with written notification to the institution director or designee. This will not affect my right to change my decision at a later date. If I withdraw consent after a medication is started, I realize that the medication may not be discontinued immediately. Rather, it will be tapered as rapidly as medically safe and then discontinued so as to prevent an adverse medical consequence, such as seizures, due to rapid medication withdrawal.

2. Questions regarding this medication can be discussed with the Interdisciplinary Team, including the physician. The staff contact person can assist in making any necessary arrangements.

3. Questions regarding any behavior support plan or behavior intervention plan, which correspond with the use of the medication, can be directed to the client’s social worker, case manager, or psychologist.

4. I have the right to request a review at any time of my record, pursuant to § 51.30(4)(d) or § 51.30(5)(b).

5. I have a legal right to file a complaint if I feel that client rights have been inappropriately restricted. The client’s social worker, case manager, or agency/facility client rights specialist may be contacted for assistance.

6. My consent permits the dose to be changed within the **anticipated dosage range** without signing another consent.

7. As parent/guardian (POA-HC) was not available for signature, he/she was verbally informed of the information in this consent.

---

**DATE SIGNED**

- **Client – If Presumed Competent to Consent/Parent of Minor/Guardian (POA-HC)**
  - Relationship to Client
    - [ ] Self
    - [ ] Parent
    - [ ] Guardian (POA-HC)

- **Staff Present at Oral Discussion**
  - Title

**Client / Parent of Minor / Guardian (POA-HC) Comments**

---

**Verbal Consent**

- **Obtained by – PRINT – Staff Name**
  - Date Obtained
  - Written Consent Received
    - [ ] Yes
    - [ ] No

- **Obtained from – PRINT – Parent / Guardian (POA-HC) Name**
  - Date Expires
  - Date Received